CD19 and B-cell chronic lymphocytic leukemia: Of the CD19 CAR T-cells currently approved for clinical use in B-cell malignancies, only brexucabtagene autoleucel (Brexu-cel), and lisocabtagene maraleucel (Liso-cel) have been investigated in CLL [159,160,161,162,163,164,165,166,167,168].